Clinical trials have been held using activators of Cxs and Panx channels such as rotigaptide for treating atrial fibrillation (NCT00137332) and endothelial dysfunction (NCT00901563), and Cx43 inhibitors for the treatment of severe ocular surface burns. This evidence concerns the gene GJA1 and atrial fibrillation.